Revised forecast
Fiscal year ending December 2026 · Full yearPrevious forecast published 15 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
The launch of Bondlido in the United States is expected to take place in the fourth quarter, later than anticipated when the contract terms were agreed, resulting in lower projected net sales. Patient enrollment in the Phase 2 clinical trial of MRX-4TZT has been delayed beyond initial expectations, and some of the planned expenses are expected to be deferred to the fiscal year ending December 2027.
| Item | Details |
|---|---|
| Net Sales | 507 million yen → 385 million yen（-24.1%） |
| Operating profit | -1,472 million yen → -1,206 million yen |
| Ordinary income | -1,472 million yen → -1,197 million yen |
| Profit attributable to owners of the parent | -1,502 million yen → -1,202 million yen |
| Net income per share | -25.3 yen and sen → -19.95 yen and sen |
| Fiscal Period Covered | Fiscal year ending December 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 15 May 2026 |
| Previous-period results | Net sales ¥128 million, operating loss ¥941 million, ordinary loss ¥937 million, net loss attributable to owners of the parent ¥937 million, basic loss per share ¥17.44 |
| Reason for the revision | The launch of Bondlido in the United States is expected to take place in the fourth quarter, later than anticipated when the contract terms were agreed, resulting in lower projected net sales. Patient enrollment in the Phase 2 clinical trial of MRX-4TZT has been delayed beyond initial expectations, and some of the planned expenses are expected to be deferred to the fiscal year ending December 2027. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The launch of Bondlido in the United States is expected to take place in the fourth quarter, later than initially anticipated, resulting in lower projected net sales. In addition, patient enrollment in the Phase 2 clinical trial of MRX-4TZT has been delayed, and some of the planned expenses are expected to be deferred to the fiscal year ending December 2027.